Clinical Trial: IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency

U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07686692) titled 'IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency' on June 30.

Brief Summary: This randomized, double-blind, placebo-controlled clinical trial evaluates intravenous ferric derisomaltose in older adults with HFpEF and iron deficiency.

Study Start Date: Aug., 2026

Study Type: INTERVENTIONAL

Condition: Heart Failure With Preserved Ejection Fraction Iron Deficiency

Intervention: DRUG: Ferric derisomaltose

Intravenous ferric derisomaltose dose is determined by participant body weight and baseline hemoglobin and ranges from 500 mg to 2000 mg, administered as a single infusion. ...